Search company, investor...

Mimetogen Pharmaceuticals


Series B - II | Alive

Total Raised




Last Raised

$800K | 9 yrs ago

About Mimetogen Pharmaceuticals

Mimetogen is actively pursuing the development of novel small molecule compounds to treat neurodegenerative diseases of the eye, including dry eye, glaucoma and retinitis pigmentosa. The company designs and develops small molecule drugs that mimic the effects of neurotrophins, proteins that help maintain the health and growth of many cells and tissues found in the eye. Making drugs that can mimic the large natural molecules may lead to the development of novel approaches to treat degenerative ocular diseases such as glaucoma, retinitis pigmentosa, age-related macular degeneration and dry eye.

Headquarters Location

1000 de La Gauchetière Street West Suite 900

Montreal, Quebec, H3B 5H4,


Missing: Mimetogen Pharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Mimetogen Pharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Mimetogen Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Mimetogen Pharmaceuticals is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Mimetogen Pharmaceuticals Patents

Mimetogen Pharmaceuticals has filed 1 patent.

The 3 most popular patent topics include:

  • Designer drugs
  • V8SuperTourer drivers
  • Water ice
patents chart

Application Date

Grant Date


Related Topics




V8SuperTourer drivers, Water ice, Designer drugs, Crystallography, Metal halides


Application Date


Grant Date



Related Topics

V8SuperTourer drivers, Water ice, Designer drugs, Crystallography, Metal halides



Latest Mimetogen Pharmaceuticals News

Phentolamine mesylate ophthalmic solution may have utility in presbyopia

Jan 25, 2021

Disclosures: Pepose reports he serves on the medical advisory board for Ocuphire Pharma and receives personal fees from AcuFocus, Kala Pharmaceuticals, Keeler, MG Therapeutics, Mimetogen Pharmaceuticals, Novartis, Ocunexus Therapeutics, Okogen, Stuart Pharmaceuticals, Sun Pharma, Thea Pharma, TearLab and Ocuphire. Please see the study for all other authors’ relevant financial disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact . Back to Healio Phentolamine mesylate ophthalmic solution improved distance corrected near visual acuity and reduced pupil diameter in patients with glaucoma and presbyopia, according to a study. “ Presbyopia has a significantly negative impact on quality of life. ... Currently, there are no pharmacological therapies approved for presbyopia, but there is some evidence that decreasing pupil diameter, optimally to a size of 1.6 mm to 2 mm to create a ‘pinhole’ effect, can improve visual acuity by increasing the depth of focus via pseudoaccommodation,” Jay S. Pepose, MD, PhD, and colleagues wrote. “This trial studied the safety and efficacy of 1% PMOS, an alpha-1 antagonist, as a drug candidate to lower IOP in glaucoma patients and, in parallel, to modulate pupil diameter and improve visual acuity in refractive conditions such as presbyopia and [dim light vision disturbances].” In the ORION-1 double-masked, placebo-controlled, multiple-dose phase 2b trial, researchers randomly assigned 39 patients with elevated IOP 1:1 to receive one evening dose of either 1% phentolamine mesylate ophthalmic solution (PMOS) (19 patients) or placebo (20 patients) for 14 days. Treatment study visits occurred on day 8, day 15 and day 16; study outcomes included mean change in diurnal IOP as well as changes in pupil diameter, distance corrected near visual acuity (DCNVA) and conjunctival hyperemia. PMOS did not significantly decrease diurnal IOP compared with placebo, but it did yield a mean 20% reduction in pupil diameter sustained for 36 hours after dosing. Further analysis showed PMOS demonstrated an IOP decrease in patients with lower IOP baseline measurements at day 8 (P = .049), but the difference was not significant at day 15. Compared with placebo, patients in the study arm achieved one or more lines of DCNVA improvement at day 8 (P = .0018), day 15 (P = .0072) and day 16 (P = .0163) under both mesopic and photopic conditions. There was no statistical difference in conjunctival hyperemia between the study arm and the placebo arm. “This trial found that 1% PMOS did not reduce IOP in patients with glaucoma or [ocular hypertension]. However, statistically significant decreases in pupil size and improvements in DCNVA were seen, which may be clinically relevant in ocular diseases with pupil modulation as a solution, such as presbyopia and [dim light vision disturbances],” Pepose and colleagues wrote. “PMOS has been studied in patients ranging from 18 to 81 years of age, and further trials should be explored to use PMOS eye drops for pupil modulation indications or potentially [normotensive glaucoma].” Read more about:

Mimetogen Pharmaceuticals Frequently Asked Questions (FAQ)

  • Where is Mimetogen Pharmaceuticals's headquarters?

    Mimetogen Pharmaceuticals's headquarters is located at 1000 de La Gauchetière Street West, Montreal.

  • What is Mimetogen Pharmaceuticals's latest funding round?

    Mimetogen Pharmaceuticals's latest funding round is Series B - II.

  • How much did Mimetogen Pharmaceuticals raise?

    Mimetogen Pharmaceuticals raised a total of $2.8M.

  • Who are the investors of Mimetogen Pharmaceuticals?

    Investors of Mimetogen Pharmaceuticals include Medwell Capital, Inovia Capital and VIMAC Ventures.

  • Who are Mimetogen Pharmaceuticals's competitors?

    Competitors of Mimetogen Pharmaceuticals include Reata Pharmaceuticals, Bellicum Pharmaceuticals, VentiRx Pharmaceuticals, Theraclone Sciences, GlycoMimetics and 13 more.

Compare Mimetogen Pharmaceuticals to Competitors

AiRNA Pharmaceuticals

AiRNA's focus is to develop RNAi drugs for cancer, inflammation, and infectious diseases.

ISA Pharmaceuticals

ISA Pharmaceuticals (Immune System Activation) is dedicated to fighting cancer and infectious diseases by providing ways to activate the patients immune system. Building on the work by internationally renowned tumor-immunology researcher Professor Kees Melief at the Leiden University Medical Center, the Netherlands, ISA Pharmaceuticals focuses on the development of synthetic peptide vaccines that boost the bodys immune system to recognize specific peptides associated with specific types of cancer and subsequently destroy the tumor cells. Thanks to a recent by the Melief-group, clinical studies (phase I/II) are showing highly promising results. The is the use of long peptides in therapeutic vaccines. This synthetic long peptide concept (SLP)aims to enable the activation of both cytotoxic T-cells (killer cells) and T-helper cells, which leads to activity of the immune systems against a tumor.


Favrille is a developer of cancer and autoimmune disease immuno-therapeutics.

Y's Therapeutics

Y's Therapeutics focuses on developing monoclonal antibody therapies and other molecular-targeted biological drugs for the treatment of inflammation-mediated diseases, cancer, and other unmet medical needs. The company also have small molecule compounds in the company's R&D pipeline to diversify the company's portfolio.

Bexion Pharmaceuticals

Bexion Pharmaceuticals is a company focused on the development of cures for cancer. Specifically, the company is interested in first entering the clinic with a glioma cancer indication, possibly simultaneously with a leukemia or pancreatic cancer indication.


Oxagen is a biopharmaceutical company that develops small molecule drugs for inflammatory and respiratory diseases.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.